Aridis' shares rise in muted market debut
August 14, 2018 at 10:27 AM EDT
Biotechnology company Aridis Pharmaceuticals Inc rose as much as 5.4 percent to $13.70 in its U.S. market debut on Tuesday, joining a host of other small-cap biotechs that have gone public this year.
